Anti-CO9/ C9/ ARMD15D monoclonal antibody

Anti-CO9/ C9/ ARMD15D antibody for FACS & in-vivo assay

Target products collectionGo to C9/C9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2425-Ab-1/ GM-Tg-hg-MP2425-Ab-2Anti-Human C9 monoclonal antibodyHuman
GM-Tg-rg-MP2425-Ab-1/ GM-Tg-rg-MP2425-Ab-2Anti-Rat C9 monoclonal antibodyRat
GM-Tg-mg-MP2425-Ab-1/ GM-Tg-mg-MP2425-Ab-2Anti-Mouse C9 monoclonal antibodyMouse
GM-Tg-cynog-MP2425-Ab-1/ GM-Tg-cynog-MP2425-Ab-2Anti-Cynomolgus/ Rhesus macaque C9 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2425-Ab-1/ GM-Tg-felg-MP2425-Ab-2Anti-Feline C9 monoclonal antibodyFeline
GM-Tg-cang-MP2425-Ab-1/ GM-Tg-cang-MP2425-Ab-2Anti-Canine C9 monoclonal antibodyCanine
GM-Tg-bovg-MP2425-Ab-1/ GM-Tg-bovg-MP2425-Ab-2Anti-Bovine C9 monoclonal antibodyBovine
GM-Tg-equg-MP2425-Ab-1/ GM-Tg-equg-MP2425-Ab-2Anti-Equine C9 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2425-Ab-1/ GM-Tg-hg-MP2425-Ab-2; GM-Tg-rg-MP2425-Ab-1/ GM-Tg-rg-MP2425-Ab-2;
GM-Tg-mg-MP2425-Ab-1/ GM-Tg-mg-MP2425-Ab-2; GM-Tg-cynog-MP2425-Ab-1/ GM-Tg-cynog-MP2425-Ab-2;
GM-Tg-felg-MP2425-Ab-1/ GM-Tg-felg-MP2425-Ab-2; GM-Tg-cang-MP2425-Ab-1/ GM-Tg-cang-MP2425-Ab-2;
GM-Tg-bovg-MP2425-Ab-1/ GM-Tg-bovg-MP2425-Ab-2; GM-Tg-equg-MP2425-Ab-1/ GM-Tg-equg-MP2425-Ab-2
Products NameAnti-C9 monoclonal antibody
Formatmab
Target NameC9
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-C9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CO9/ C9/ ARMD15D VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLPm002710mouse C9 Lentivirus plasmid
    ORF Viral VectorvGMLPm002710mouse C9 Lentivirus particle


    Target information

    Target IDGM-MP2425
    Target NameC9
    Gene ID735,12279,117512,694223,479354,101096948,526766,100034183
    Gene Symbol and SynonymsARMD15,C9,C9D
    Uniprot AccessionP02748,Q62930,Q3MHN2,P48770
    Uniprot Entry NameCO9_HUMAN,CO9_RAT,CO9_BOVIN,CO9_HORSE
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseLung Cancer, Diabetic Nephropathy
    Gene EnsemblENSG00000113600
    Target ClassificationN/A

    The target: C9, gene name: C9, also named as ARMD15D, C9. This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.